Vivid Dx
Latest round
- Seed
Last raised
- Jul 2026
Total raised
- $15M
Investors
- 3
About Vivid Dx
Founded in 2022 and headquartered in Oxford, UK by Jeff Liu (CTO), Vivid Dx develops advanced diagnostic platforms for rapid pathogen detection. The platform aims to revolutionize diagnostic processes for healthcare providers. Vivid Dx specializes in the development of advanced diagnostic technologies designed to enhance the speed and accuracy of pathogen identification, specifically targeting sepsis-causing pathogens and antimicrobial resistance. Their core product, a next-generation diagnostic platform, utilizes Raman spectroscopy to analyze the biochemical fingerprints of single cells, facilitating rapid pathogen detection directly from blood samples. The solutions are positioned primarily for healthcare providers, including hospitals and clinical laboratories, aiming to transform diagnostics and improve patient outcomes. Vivid Dx's products are marketed in regions such as North America and Europe, serving a client base that includes healthcare institutions seeking to optimize their diagnostic processes. Vivid Dx generates revenue primarily through business-to-business transactions with healthcare providers and clinical laboratories, leveraging subscription models and direct sales of their diagnostic platforms. Clients engage with the company through various partnership agreements, which may include licensing arrangements for the proprietary technology or subscription-based access to the diagnostic platform and associated services. The revenue structure is bolstered by the flagship diagnostic offerings, which aim to significantly reduce the time from infection detection to treatment decision-making. These services are designed to improve outcomes and lower costs, reinforcing the value proposition for healthcare providers. Pricing details for specific products and services are tailored to meet the needs of individual clients, ensuring alignment with the operational requirements of the healthcare institutions they serve. The company aims to launch upcoming products designed to enhance diagnostic capabilities, with a focus on global expansion into new markets by the end of 2027. Recent preclinical tests showed approximately 99% pathogen identification accuracy, setting a solid foundation for their future growth initiatives.
Who invested in Vivid Dx
3 investors across 1 round
See all investors in Vivid Dx
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Seed
Jul 28, 2026
Amount
$15M
Investors
Questions about Vivid Dx
Who invested in Vivid Dx?
Vivid Dx has 3 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Vivid Dx raised?
Vivid Dx has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Vivid Dx last raise money?
Vivid Dx's most recent round on record is a Seed, in Jul 2026.
What does Vivid Dx do?
Founded in 2022 and headquartered in Oxford, UK by Jeff Liu (CTO), Vivid Dx develops advanced diagnostic platforms for rapid pathogen detection.
Where is Vivid Dx headquartered?
Vivid Dx is headquartered in Oxford, UK.
Which VCs invest in companies like Vivid Dx?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Balderton Capital back healthcare it companies at Vivid Dx's stage. Their profiles are linked below.
VCs backing healthcare it startups at Seed
Raising like Vivid Dx? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.